New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...

A large retrospective study, the first of its kind, reported reduced rates of EO-CRC in patients younger than 50 years of age ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

GLP-1 RAs can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight.

GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a ...

Glucagon-like peptide medications that treat Type 2 diabetes and weight management continue to grow in popularity, though ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor ...

November is National Diabetes Month, as the disease affects about 38 million Americans, including kids. Diabetes occurs when ...

Semaglutide, the main ingredient in Ozempic and Wegovy, improves type 2 diabetes, heart disease, smoking, and alcohol consumption, which all raise the risk of Alzheimer’s.

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 ...

Among patients receiving GLP-1 RAs, preexisting International Statistical Classification of Diseases and Related Health Problems, Tenth Revision encounter diagnosis codes of type 2 diabetes (46.2% ...